Role of FDG PET/CT in Patients With Metastasis of Unknown Origin

Assiut University

Status: Not yet enrolling

Conditions: Metastasis

Treatments: Device: PET/CT

Study type: Observational

Funder types: Other

Identifiers

NCT06055764

PET/CT in MUO

Details and patient eligibility

About

Evaluatation of the role of F18FDG-PET/CT in patients with metastases of unknown origin.

Full description

Cancer of unknown primary origin (CUP) includes a cluster of heterogeneous tumors that have exceptional clinical features: it is defined as early apparent metastatic disease with no recognizable primary site at the time of presentation. The incidence of CUP ranges around 2% of all new cancer diagnoses.

The work up list of CUP include; a biopsy proven malignancy, a detailed physical examination, many laboratory, radiological and endoscopy. However, these investigations may be costly time-consuming and may eventually fail to detect the site of the primary malignant tumor in the majority of patients. In this context, positron-emission tomography (PET) combined with computed tomography (PET/CT), using the radiotracer 18F fluoro- 2-deoxyglucose (FDG) is an alternative, non-invasive imaging modality with accurate diagnostic performance. It considered good tool for diagnosis of patients with CUP . The basis for use of FDG as radiotracer for PET imaging in CUP depends on the fact that most of the malignant cancer phenotypes show an increased glucose metabolism rate.

Failure to identify the primary tumor hampers optimization of management planning, which in turn may adversely influence patient prognosis.

Enrollment: 73 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with age more than 18 years presented with either pathologically proved metastases of unknown primary or
• Patients with clinico-radiological suspicious of having metastases.

Exclusion criteria

• • Age below 18 years,

  • patients with pathologically proved primary tumor,
  • Patients suffering from advanced disease and in-cooperative patients.
  • Pregnant and lactating women.
  • Patients who had motion artifacts, or those who can't stay stable or calm during acquisition.